Skip to main content
Clinical Trials/JPRN-jRCTs071190008
JPRN-jRCTs071190008
Recruiting
Phase 2

Study of Intrathecal or Intracerebroventricular administration of Cyclodextrin for Niemann-Pick disease Type C - ITaC study

Matsuo Muneaki0 sites3 target enrollmentMay 17, 2019

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
iemann-Pick disase, type C
Sponsor
Matsuo Muneaki
Enrollment
3
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 17, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Matsuo Muneaki

Eligibility Criteria

Inclusion Criteria

  • 1\)Genetically proven Niemann\-Pick disease type C
  • 2\)From two year\-old to fifteen year\-old patient with apparent neurological symptom.
  • 3\)Possibility of regular intrathecal administration by lumbar puncture.
  • 4\)Possibility of repeated regular visits to Saga University Hospital.
  • 5\)Miglustat should be taken at least three months with a constant dosage before the baseline assessment.
  • 6\)The patient or the guardian understand poor life prognosis of this intractable disease and no established treatment for it.
  • 7\)The patient or the guardian understand that the safety and efficacy of HPBCD is not established,and unexpected adverse events which can lead to a life threatening sequelae could be occurred.
  • 8\)The patient or guardian understand risks for lumber puncture.
  • 9\)The patient or guardian understand that this treatment will be done in a limited period.

Exclusion Criteria

  • 1\)The age at registration is less than two year\-old or more than sixteen year\-old.
  • 2\)No neurological symptoms.
  • 3\)Past history of hypersensitivity reaction to cyclodextrin or its additives.
  • 4\)Suspected central nervous system infection or systemic infection.
  • 5\)Difficulty of lumbar puncture due to spinal anomaly.
  • 6\)Skin infection of the lumbar puncture site.
  • 7\)Neutropenia (less than 1,000/mm3\)
  • 8\)Thrombocytopenia (less than 50,000/mm3\)
  • 9\)Circulation abnormality in cerebrospinal fluid.
  • 10\)Use of anti\-coagulants or bleeding tendancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials